Type 2 Diabetes

Insulin may not be the culprit in poorer outcomes, according to TUXEDO sub-study.

In this week's Homerun Slides, the use of genotyping in understanding the mechanisms of diabetes.

For patients in the U.S., the price of this lifesaving treatment has risen dramatically.

Researchers saw long-term reduction in end-stage renal disease, without evidence of increased risk for cardiovascular events or death.

According to a new study, people with diabetes have a slightly shorter life expectancy than people without diabetes, and many of those years will be marred by disability.

First-time data for the investigational oral formulation of Novo Nordisk's semaglutide were presented at the annual meeting of the Endocrine Society. Billed as one of the company’s brightest pipeline prospects, it has sailed through a phase II trial.

Male, 66 years of age, type 2 diabetes, class III obesity, peripheral neuropathy, multiple toe amputations, hypertension, hyperlipidemia and, most importantly, a 2-year-old granddaughter. Patient taking 100 units long-acting insulin, sulfonylurea, metformin, beta blocker, and statin. Checks glucose once in a while; in the 200 to 270 range when checks. A1C 9.3%.

In this week's Homerun Slides, explaining the beta-centric classification of diabetes mellitus.

While the risk remains low overall, a new large study showed a greater risk for pioglitazone than other diabetes drugs.

Why smokers have an increased risk of type 2.